- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04587011
A Study to Explore Pharmacokinetics/Pharmacodynamics and Safety of Tegoprazan BID Dosing in Healthy Subjects
December 23, 2020 updated by: HK inno.N Corporation
A Phase 1 Clinical Trial to Explore Pharmacokinetics, Pharmacodynamics and Safety After Twice-daily Dosing of Tegoprazan Tablets in Healthy Subjects
The main purpose of this study is to explore the pharmacokinetics, pharmacodynamics and safety after twice-daily dosing of tegoprazan tablets in healthy subjects.
Study Overview
Status
Unknown
Conditions
Detailed Description
- To explore the pharmacokinetics, pharmacodynamics and safety in accordance with the dose escalation when tegoprazan is given orally twice daily for 3 days in healthy subjects.
- To compare the pharmacodynamics and safety of tegoprazan oral administration and esomeprazole infusion for 24 hours
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Busan, Korea, Republic of, 47392
- Recruiting
- Inje University Busan Paik Hospital
-
Contact:
- Jon Lyul Kim, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy subjects aged 19 to 45(inclusive) years at screening.
- Subjects with body mass index (BMI) in the range of 18.5 kg/m^2 to 28.0 kg/m^2(inclusive)
- Subjects who voluntarily agreed to participate in the study after being fully informed of the purpose, content, and characteristics of the investigational product(IP) prior to the study participation.
Exclusion Criteria:
Past medical history
- Subjects who are determined by the investigator to have clinically significant history or disease related to the liver, kidney, digestive system, respiratory system, musculoskeletal system, endocrine system, neuropsychiatric system, hemato-oncology system, urinary system and cardiovascular system including cardiac arrhythmia.
- Subjects who are determined by the investigator to have past history of gastrointestinal diseases (ex.: gastritis, GERD, Crohn's disease, ulcers etc.) or abdominal surgery (except simple appendectomy or herniotomy) that may affect the IP absorption.
Diagnostic test and electrocardiogram (ECG)
- If H. pylori test result is positive at screening
- If the AST or ALT value is more than 1.25 times the upper limit of normal under the screening test
- If the total bilirubin value is more than 1.5 times the upper limit of normal under the screening test
- If the eGFR calculated by CKD-EPI formula is less than 80 mL/min at screening
- Subjects showing clinically significant abnormalities on ECG at screening
Allergy and drug abuse
- Subjects who are hypersensitive to the investigational product or its active ingredient and any other medications (aspirin, antibiotics etc.)
- Subjects with history of substance abuse or positive results from drug screening test.
Contraindicated drugs/foods
- Subjects who have been taking any medications (including herbal medicines) or on an abnormal diet (ex: consuming more than 1L of grapefruit juice per day, large amounts of garlic, broccoli and kale, etc.) that can affect the absorption, distribution, metabolism and excretion of the IP within 28 days from the first IP administration date
- Subjects who took any prescription drugs(ETC) or any over-the-counter drugs(OTC) within 10 days from the first IP administration date
- Subjects who participated in other clinical trials or bioequivalence test and received other investigational product within 6 months from the first day of the IP administration (allowed to participate only if the other investigational product(s) was(were) not taken)
Blood donation and transfusion
- Subjects who donated whole blood within 60 days from the first day of the investigational product administration
- Subjects who received blood transfusion or made apheresis blood donation within 30 days from the first day of the IP administration
Pregnancy, Breastfeeding, and Contraception
- Women who are pregnant, breast-feeding or have positive result on pregnancy test.
- Subjects who are unable to use medically proven dual contraceptive methods or medically acceptable contraceptive method (intrauterine device with proven pregnancy failure rate, concurrent use of physical barrier method and spermicide, vasectomy, tubectomy/ligation, and hysterectomy, etc.) by the subject or spouse or partner from the screening date to 30 days after the last IP administration date.
Others
- Subjects whose weekly alcohol intake exceeds 30g/day in the last 4 weeks prior to the screening visit or found positive on alcohol test
- Subjects who smoke more than 10 cigarettes/day per week over the last 4 weeks prior to the screening visit
- Subjects with caffeine consumption of more than 400mg/day per week over the last 4 weeks prior to the screening visit
- Subjects with clinically significant findings that the investigator determined to be unqualified for participation in the clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: T1
Tegoprazan A mg or placebo
|
Tegoprazan A mg or placebo taken orally twice daily for 3 days.
|
Experimental: T2
Tegoprazan B mg or placebo
|
Tegoprazan B mg or placebo taken orally twice daily for 3 days.
|
Experimental: T3
Tegoprazan C mg or placebo
|
Tegoprazan C mg or placebo taken orally twice daily for 3 days.
|
Experimental: T4
Tegoprazan D mg or placebo
|
Tegoprazan D mg or placebo taken orally twice daily for 3 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
Cmax of Tegoprazan and M1
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
AUC0-t of Tegoprazan and M1
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
AUC0-∞ of Tegoprazan and M1
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
Tmax of Tegoprazan and M1
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
t1/2β of Tegoprazan and M1
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
CL/F of Tegoprazan
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
Vd/F of Tegoprazan
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
Css,max of Tegoprazan and M1
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
Css,min of Tegoprazan and M1
|
Up to 24 hours
|
Pharmacokinetic Evaluation
Time Frame: Up to 24 hours
|
Css,avg of Tegoprazan and M1
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
AUC48-72h of Tegoprazan and M1
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
Tmax,ss of Tegoprazan and M1
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
t1/2β,ss of Tegoprazan and M1
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
CLss/F of Tegoprazan
|
Up to 24 hours
|
Pharmacokinetics Evaluation
Time Frame: Up to 24 hours
|
Vdss/F of Tegoprazan
|
Up to 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamics Evaluation
Time Frame: 24 hours
|
Mean pH
|
24 hours
|
Pharmacodynamics Evaluation
Time Frame: 24 hours
|
Median pH
|
24 hours
|
Pharmacodynamics Evaluation
Time Frame: 24 hours
|
TpH>4(%)
|
24 hours
|
Pharmacodynamics Evaluation
Time Frame: 24 hours
|
TpH>6(%)
|
24 hours
|
Pharmacodynamics Evaluation
Time Frame: 24 hours
|
Basal pH
|
24 hours
|
Pharmacodynamics Evaluation
Time Frame: 24 hours
|
Δ TpH>4(%)
|
24 hours
|
Pharmacodynamics Evaluation
Time Frame: 24 hours
|
Δ TpH>6(%)
|
24 hours
|
Pharmacodynamics Evaluation
Time Frame: 24 hours
|
Δ mean pH
|
24 hours
|
Pharmacodynamics Evaluation
Time Frame: 24 hours
|
Δ median pH
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jong Lyul Kim, MD, PhD, Inje University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 24, 2020
Primary Completion (Anticipated)
March 1, 2021
Study Completion (Anticipated)
June 1, 2021
Study Registration Dates
First Submitted
October 7, 2020
First Submitted That Met QC Criteria
October 7, 2020
First Posted (Actual)
October 14, 2020
Study Record Updates
Last Update Posted (Actual)
December 28, 2020
Last Update Submitted That Met QC Criteria
December 23, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- IN_APA_119
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Tegoprazan dose A or placebo
-
Pusan National University HospitalCompletedThe Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux DiseaseLaryngopharyngeal Reflux DiseaseKorea, Republic of
-
Genexine, Inc.Completed
-
Daewoong Bio Inc.CompletedDry Eye SyndromesKorea, Republic of
-
Rhythm Pharmaceuticals, Inc.Recruiting
-
PhaseBio Pharmaceuticals Inc.Completed
-
Centrexion TherapeuticsCompletedSafety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDNPainful Diabetic NeuropathyUnited States
-
Sunshine Lake Pharma Co., Ltd.RecruitingProgressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)China
-
Ventyx Biosciences, IncTerminatedPsoriatic ArthritisUnited States, Bulgaria, Czechia, Germany, Hungary, Poland, Spain
-
National Research Council, SpainUniversidad Católica San Antonio de Murcia; The Scientific and Technological...Completed
-
Harbour BioMed (Guangzhou) Co. Ltd.RecruitingPrimary Immune Thrombocytopenic PurpuraChina